These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9776997)

  • 1. Use of human recombinant erythropoietin and prednisone for treatment of myelodysplastic syndrome with erythroid predominance in a dog.
    Boone LI; Knauer KW; Rapp SW; Stewart JF; Modiano JF
    J Am Vet Med Assoc; 1998 Oct; 213(7):999-1001. PubMed ID: 9776997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
    Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of biological activity and safety of recombinant canine erythropoietin with that of recombinant human erythropoietin in clinically normal dogs.
    Randolph JF; Stokol T; Scarlett JM; MacLeod JN
    Am J Vet Res; 1999 May; 60(5):636-42. PubMed ID: 10328437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C
    Leuk Res; 2006 Apr; 30(4):385-8. PubMed ID: 16219350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R; Pagano A; Terzoli E; Amadori S
    Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes.
    Depaoli L; Levis A; Isabella N; Ficara F; Priotto C; Lista P; Foà R; Resegotti L
    Haematologica; 1993; 78(2):118-22. PubMed ID: 8349187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
    Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
    Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term erythropoietin therapy improves response in myelodysplastic syndrome.
    Ohshima M; Ubara Y; Tagami T; Sawa N; Suwabe T; Yamakawa K; Hoshino J; Katori H; Takemoto F; Hara S; Miyakoshi J; Takaichi K
    Ther Apher Dial; 2005 Aug; 9(4):362-6. PubMed ID: 16076383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes.
    Musto P; Villani O; Martorelli MC; Pietrantuono G; Guariglia R; Mansueto G; D'Auria F; Grieco V; Bianchino G; Sparano A; Zonno A; Lerose R; Sanpaolo G; Falcone A
    Leuk Res; 2010 Aug; 34(8):981-5. PubMed ID: 19931907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders.
    Cortelezzi A; Colombo G; Pellegrini C; Silvestris I; Moronetti Mazzeo L; Bosari S; Lambertenghi Deliliers G; Fracchiolla NS
    Am J Hematol; 2008 Jul; 83(7):531-9. PubMed ID: 18383321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
    Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
    Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sequential treatment with granulocyte-colony stimulating factor (GCSF) and human recombinant erythropoietin (rH-EPO) in anemia of a patient with myelodysplastic syndrome and high blood transfusion requirements)].
    Borbolla-Escoboza JR; González-Avante CM; López-Hernández MA; Flores-Chapa JD; Collados-Larumbe MT
    Gac Med Mex; 1997; 133(4):355-9. PubMed ID: 9410796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
    Musch E; Malek M; Chrissafidou A
    Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term case study of myelodysplastic syndrome in a dog.
    Miyamoto T; Horie T; Shimada T; Kuwamura M; Baba E
    J Am Anim Hosp Assoc; 1999; 35(6):475-81. PubMed ID: 10580906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.